CN114814060B - 一种缬沙坦氨氯地平片有关物质的检测方法 - Google Patents
一种缬沙坦氨氯地平片有关物质的检测方法 Download PDFInfo
- Publication number
- CN114814060B CN114814060B CN202110119769.5A CN202110119769A CN114814060B CN 114814060 B CN114814060 B CN 114814060B CN 202110119769 A CN202110119769 A CN 202110119769A CN 114814060 B CN114814060 B CN 114814060B
- Authority
- CN
- China
- Prior art keywords
- solution
- valsartan
- impurity
- preparing
- amlodipine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000004072 C09CA03 - Valsartan Substances 0.000 title claims abstract description 58
- 229960004699 valsartan Drugs 0.000 title claims abstract description 58
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 title claims abstract description 57
- 229960000528 amlodipine Drugs 0.000 title claims abstract description 51
- 238000001514 detection method Methods 0.000 title claims abstract description 24
- 239000000126 substance Substances 0.000 title claims abstract description 15
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 title abstract 5
- 239000012535 impurity Substances 0.000 claims abstract description 50
- 238000004128 high performance liquid chromatography Methods 0.000 claims abstract description 23
- 238000012360 testing method Methods 0.000 claims abstract description 23
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims abstract description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 10
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 4
- 239000007853 buffer solution Substances 0.000 claims abstract description 3
- UNXNGGMLCSMSLH-UHFFFAOYSA-N dihydrogen phosphate;triethylazanium Chemical compound OP(O)(O)=O.CCN(CC)CC UNXNGGMLCSMSLH-UHFFFAOYSA-N 0.000 claims abstract description 3
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 claims description 54
- 239000000243 solution Substances 0.000 claims description 22
- 239000003085 diluting agent Substances 0.000 claims description 20
- 239000011550 stock solution Substances 0.000 claims description 20
- 239000012488 sample solution Substances 0.000 claims description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- 229960004005 amlodipine besylate Drugs 0.000 claims description 10
- 239000013558 reference substance Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 239000000523 sample Substances 0.000 claims description 7
- BXWLVQXAFBWKSR-UHFFFAOYSA-N 2-methoxy-5-methylsulfonylbenzoic acid Chemical compound COC1=CC=C(S(C)(=O)=O)C=C1C(O)=O BXWLVQXAFBWKSR-UHFFFAOYSA-N 0.000 claims description 6
- 230000003044 adaptive effect Effects 0.000 claims description 6
- 238000007865 diluting Methods 0.000 claims description 6
- 239000011259 mixed solution Substances 0.000 claims description 6
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 5
- 239000005695 Ammonium acetate Substances 0.000 claims description 5
- 229940043376 ammonium acetate Drugs 0.000 claims description 5
- 235000019257 ammonium acetate Nutrition 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 239000012085 test solution Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 238000010828 elution Methods 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000000047 product Substances 0.000 claims description 2
- 239000012088 reference solution Substances 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- 238000009210 therapy by ultrasound Methods 0.000 claims description 2
- 238000000926 separation method Methods 0.000 abstract description 6
- 238000003908 quality control method Methods 0.000 abstract description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- HQQARYRCDMYLHW-UHFFFAOYSA-N N,N-diethyl-2-[(2-methoxy-5-methylsulfonylbenzoyl)amino]ethanamine oxide Chemical compound CC[N+]([O-])(CC)CCNC(=O)C1=CC(S(C)(=O)=O)=CC=C1OC HQQARYRCDMYLHW-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 230000003276 anti-hypertensive effect Effects 0.000 description 3
- 239000012490 blank solution Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- SMMXTJMPESFCOQ-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-2-hydroxy-5-methylsulfonylbenzamide Chemical compound CCN(CC)CCNC(=O)C1=CC(S(C)(=O)=O)=CC=C1O SMMXTJMPESFCOQ-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 208000035859 Drug effect increased Diseases 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- -1 valsartan amlodipine compound Chemical class 0.000 description 1
- 229940043102 valsartan and amlodipine Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N2030/022—Column chromatography characterised by the kind of separation mechanism
- G01N2030/027—Liquid chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8872—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample impurities
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
时间(分钟) | 流动相A(%) | 流动相B(%) |
0 | 75 | 25 |
5 | 75 | 25 |
22 | 50 | 50 |
30 | 50 | 50 |
40 | 20 | 80 |
50 | 20 | 80 |
50.1 | 75 | 25 |
70 | 75 | 25 |
物质名称 | 保留时间(分钟) | 相对保留时间 | 分离度 | 拖尾因子 |
杂质III | 4.519 | 0.25 | -/18.8 | 1.1 |
杂质IX | 8.913 | 0.50 | 18.8/3.7 | 1.0 |
杂质VIII | 10.035 | 0.56 | 3.7/20.6 | 1.0 |
杂质V | 15.011 | 0.84 | 20.6/4.0 | 1.0 |
杂质VII | 15.72 | 0.88 | 4.0/11.5 | 1.0 |
氨氯地平 | 17.875 | 1.00 | 11.5/11.4 | 1.4 |
杂质VI | 20.014 | 1.12 | 11.4/2.1 | 1.0 |
杂质II | 24.129 | 1.35 | 17.4/13.1 | 1.0 |
缬沙坦 | 27.123 | 1.52 | 13.1/11.2 | 0.8 |
杂质IV | 38.006 | 2.13 | 25.5/25.7 | 1.0 |
杂质I | 43.815 | 2.45 | 25.7/- | 1.0 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110119769.5A CN114814060B (zh) | 2021-01-28 | 2021-01-28 | 一种缬沙坦氨氯地平片有关物质的检测方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110119769.5A CN114814060B (zh) | 2021-01-28 | 2021-01-28 | 一种缬沙坦氨氯地平片有关物质的检测方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114814060A CN114814060A (zh) | 2022-07-29 |
CN114814060B true CN114814060B (zh) | 2024-05-10 |
Family
ID=82525433
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110119769.5A Active CN114814060B (zh) | 2021-01-28 | 2021-01-28 | 一种缬沙坦氨氯地平片有关物质的检测方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114814060B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115684445A (zh) * | 2022-10-27 | 2023-02-03 | 海南葫芦娃药业集团股份有限公司 | 一种缬沙坦氨氯地平药物组合物中有关物质的检测方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102670485A (zh) * | 2012-06-11 | 2012-09-19 | 华润赛科药业有限责任公司 | 含缬沙坦的固体组合物中水解杂质h的研究及控制方法 |
CN102846625A (zh) * | 2012-10-18 | 2013-01-02 | 海口华仕联医药科技有限公司 | 一种稳定的缬沙坦、氨氯地平和氢氯噻嗪的药物组合及其制备方法 |
CN103127131A (zh) * | 2012-07-27 | 2013-06-05 | 华润赛科药业有限责任公司 | 含缬沙坦的固体组合物及其制备方法 |
CN104840460A (zh) * | 2014-02-13 | 2015-08-19 | 长春海悦药业有限公司 | 一种含有缬沙坦和氨氯地平的药物组合物 |
WO2018199636A1 (en) * | 2017-04-26 | 2018-11-01 | Alvogen Korea Co.,Ltd. | A combination formulation comprising hmg-coa reductase inhibitor and calcium channel blocker |
CN110133149A (zh) * | 2019-05-31 | 2019-08-16 | 重庆三圣实业股份有限公司 | 一种分离测定lcz696及其杂质的方法 |
CN111551651A (zh) * | 2020-06-18 | 2020-08-18 | 丽珠集团丽珠制药厂 | 缬沙坦药物组合物中杂质k的检测方法 |
-
2021
- 2021-01-28 CN CN202110119769.5A patent/CN114814060B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102670485A (zh) * | 2012-06-11 | 2012-09-19 | 华润赛科药业有限责任公司 | 含缬沙坦的固体组合物中水解杂质h的研究及控制方法 |
CN103127131A (zh) * | 2012-07-27 | 2013-06-05 | 华润赛科药业有限责任公司 | 含缬沙坦的固体组合物及其制备方法 |
CN102846625A (zh) * | 2012-10-18 | 2013-01-02 | 海口华仕联医药科技有限公司 | 一种稳定的缬沙坦、氨氯地平和氢氯噻嗪的药物组合及其制备方法 |
CN104840460A (zh) * | 2014-02-13 | 2015-08-19 | 长春海悦药业有限公司 | 一种含有缬沙坦和氨氯地平的药物组合物 |
WO2018199636A1 (en) * | 2017-04-26 | 2018-11-01 | Alvogen Korea Co.,Ltd. | A combination formulation comprising hmg-coa reductase inhibitor and calcium channel blocker |
CN110133149A (zh) * | 2019-05-31 | 2019-08-16 | 重庆三圣实业股份有限公司 | 一种分离测定lcz696及其杂质的方法 |
CN111551651A (zh) * | 2020-06-18 | 2020-08-18 | 丽珠集团丽珠制药厂 | 缬沙坦药物组合物中杂质k的检测方法 |
Non-Patent Citations (5)
Title |
---|
New Stability Indicating Method for Quantification of Impurities in Amlodipine and Valsartan Tablets by Validated HPLC;Rama Joga Venkata Erank 等;ISRN Medicinal Chemistry;全文 * |
Simultaneous Determination of Amlodipine Besylate, Valsartan and Its Related Substances in Their Film-Coated Tablets Dosage Form by RP-HPLC Method;Mahmoud Abdelfatah Mohamed;Advanced Journal of Chemistry-Section A;第2卷;全文 * |
缬沙坦氨氯地平双层片的研制及放大生产;胡李斌;CNKI硕士电子期刊 医药卫生科技辑(第1期);第1-10页 * |
缬沙坦氨氯地平片有关物质研究;周志勇 等;安徽医药(04);全文 * |
高效液相色谱法测定缬沙坦氨氯地平片中的有关物质;荆小燕 等;中国新药杂志(19);全文 * |
Also Published As
Publication number | Publication date |
---|---|
CN114814060A (zh) | 2022-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mirza et al. | Determination of captopril in pharmaceutical tablets by anion-exchange HPLC using indirect photometric detection; a study in systematic method development | |
CN106706768B (zh) | 一种分离测定恩格列净及其有关物质的方法 | |
CN104749269A (zh) | 一种利用hplc测定阿格列汀原料药及制剂中对映异构体杂质的方法 | |
CN106596798B (zh) | 一种氢溴酸沃替西汀中有关物质的分析方法 | |
CN102375033B (zh) | 盐酸苯达莫司汀及其有关物质的高效液相色谱分析方法 | |
CN108152418B (zh) | 酮咯酸氨丁三醇或其制剂中酮咯酸氨丁三醇或/和杂质的hplc检测方法 | |
CN114814060B (zh) | 一种缬沙坦氨氯地平片有关物质的检测方法 | |
CN113009060A (zh) | 高效液相色谱法测定盐酸羟考酮含量的方法 | |
CN110927279B (zh) | 一种盐酸咪达普利有关物质的分离方法 | |
CN108030924A (zh) | 一种高稳定性阿瑞匹坦组合物的制备方法 | |
Raggi et al. | A rapid LC method for the identification and determination of CNS drugs in pharmaceutical formulations | |
CN102636600B (zh) | 一种测定盐酸帕洛诺司琼组合物中光学异构体的方法 | |
CN110286162B (zh) | 一种含对乙酰氨基酚、氢溴酸右美沙芬和琥珀酸多西拉敏的药物制剂溶出度的测定方法 | |
Mabrouk et al. | Development and application of a novel, dual-mode gradient, stability-indicating HPLC-DAD method for the simultaneous determination and purity assessment of mebeverine hydrochloride, diloxanide furoate and their corresponding major degradation products in combination with some gastrointestinal drugs in the form of oral doses | |
CN103063778B (zh) | 拉米夫定有关物质检查的分析方法 | |
CN115032284A (zh) | 一种分离检测咀嚼片中有关物质的方法 | |
CN110108810B (zh) | 一种含对乙酰氨基酚、氢溴酸右美沙芬和盐酸去氧肾上腺素的药物制剂溶出度的测定方法 | |
CN114076801B (zh) | 一种来那度胺中有关物质的检测方法 | |
CN106442793B (zh) | 一种制备阿法替尼的中间体及其对映异构体的检测方法 | |
CN110208397A (zh) | 一种同时测定土霉素氟尼辛注射液中两种主药含量的高效液相色谱法 | |
CN110554099A (zh) | 盐酸帕洛诺司琼注射液或原料药中杂质c、杂质d及对映异构体的分析方法 | |
CN109270178B (zh) | 一种高效液相色谱法分离测定度他雄胺软胶囊中度他雄胺及有关物质的方法 | |
CN112557558B (zh) | 一种检测依折麦布辛伐他汀片中sch59566杂质含量的方法 | |
CN112858527B (zh) | 盐酸普拉克索缓释片有关物质的检测方法 | |
CN111458431B (zh) | 奥利司他中间体的异构体的检测方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: 201203 Building 1, Lane 647, Songtao Road, Zhangjiang High Tech Park, Pudong New Area, Shanghai Applicant after: Shanghai Yunshengyan neoplasm Technology Co.,Ltd. Applicant after: SHENZHEN LANGBO BIOMEDICAL Co.,Ltd. Address before: 201203 Building 1, Lane 647, Songtao Road, Zhangjiang High Tech Park, Pudong New Area, Shanghai Applicant before: SHANGHAI BOCIMED PHARMACEUTICAL Co.,Ltd. Applicant before: SHENZHEN LANGBO BIOMEDICAL Co.,Ltd. |
|
CB02 | Change of applicant information | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20230807 Address after: 201306 building 24, No. 356, ZHENGBO Road, Lingang xinpian District, China (Shanghai) pilot Free Trade Zone, Fengxian District, Shanghai Applicant after: Shanghai bozhiyan new drug research Co.,Ltd. Applicant after: SHENZHEN LANGBO BIOMEDICAL Co.,Ltd. Address before: 201203 Building 1, Lane 647, Songtao Road, Zhangjiang hi tech park, Zhangjiang hi tech park, Pudong New Area, Shanghai Applicant before: Shanghai Yunshengyan neoplasm Technology Co.,Ltd. Applicant before: SHENZHEN LANGBO BIOMEDICAL Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant |